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Abstract 
 
Dipeptidyl-peptidase IV (DPPIV) (E.C.3.4.14.5.) is a 110 KDa peptidase expressed in almost 
every tissue of the human body. DPPIV expression is altered in obese conditions. Preliminary studies 
in our laboratory showed that this enzyme stimulates pre-adipocyte differentiation and lipid 
accumulation using a murine pre-adipocyte cell line. Vildagliptin, sitagliptin and saxagliptin are a new 
class of DPPIV selective inhibitors used in diabetes to increase the half-life of some insulin-stimulating 
hormones. The aim of this study is to evaluate, the effect of gliptins on the adipose tissue formation 
(adipogenesis and lipolysis). Using a pre-adipocyte murine cell line, 3T3-L1 we analysed the effect of 
gliptins on lipid accumulation. Our results showed that gliptins reduced both basal and stimulated lipid 
accumulation. We further evaluated if gliptins could modulate lipolysis or adipogenesis. Our studies 
show that gliptins do not induce lipolysis but play an inhibitory role on adipogenesis. This inhibition is 
achieved by inhibiting the expression of a transcription factor crucial for adipocyte differentiation, 
PPARγ. It was also observed that gliptins inhibit lipid accumulation through PKA pathway. 
Neuropeptide Y (NPY) is a DPPIV substrate that acts through six G-protein-coupled receptors: 
Y1, Y2, Y3, Y4, Y5 and y6. Previous studies in our lab showed that DPPIV stimulates lipid accumulation 
through cleavage of NPY1-36 into NPY3-36. The cleaved peptide stimulates lipid accumulation through 
Y2 receptor activation. The second aim of our study was to evaluate the effect of gliptins on NPY-
stimulated lipid accumulation. Our results show that gliptins inhibit NPY-induced lipid accumulation. 
We also analysed the intracellular mechanism of action of NPY and conclude that NPY stimulates lipid 
accumulation through modulation of PKA.  
The present study suggests that gliptins can be used as new putative pharmacological 
strategies to prevent adipose tissue increase without the risk of dyslipidemia. 
 
Key words: Dipeptidyl-peptidase IV; Gliptin; Neuropeptide Y; Adipocyte; Protein Kinase A 
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Resumo 
 
 
A Dipeptidyl-peptidase IV (DPPIV) (E.C.3.4.14.5.) é uma peptidase de 110 KDa expressa em 
quase todos os tecidos do corpo humano. A sua expressão encontra-se alterada em situações de 
obesidade. Estudos anteriores, realizados no nosso laboratório, demonstraram que a DPPIV estimula 
a diferenciação de adipócitos e a acumulação lipídica nos adipócitos. A vildagliptina, a sitagliptina e a 
saxagliptina fazem parte de uma nova classe de inibidores selectivos da DPPIV cuja função principal 
é aumentar o tempo de meia vida de algumas hormonas responsáveis pelo estímulo da produção de 
insulina. O objectivo principal deste trabalho consiste em avaliar o efeito que as gliptinas têm na 
formação do tecido adiposo (adipogénese e lipólise). Usando uma linha celular de pre-adipócitos de 
murganho (3T3-L1), foi testado o efeito das gliptinas na acumulação lipídica. Os resultados obtidos 
demonstram que as gliptinas reduzem tanto a acumulação lipídica basal como a acumulação lipídica 
induzida pela insulina. De seguida avaliámos se as gliptinas exerciam efeito na lipólise ou na 
adipogénese. Verificámos que apesar de as gliptinas não provocarem lipólise, têm um efeito inibitório 
na adipogénese. Esta inibição ocorre pela inibição da expressão de um factor de transcrição, PPARγ, 
crucial para a diferenciação dos adipócitos. Observámos ainda que as gliptinas inibem a acumulação 
lipídica via PKA. 
O neuropéptido Y (NPY) é um conhecido substrato da DPPIV cuja acção ocorre pela 
activação de seis receptores acoplados à proteína G: Y1, Y2, Y3, Y4, Y5 e y6. Estudos anteriores 
realizados no nosso laboratório demonstraram que a DPPIV estimula a acumulação lipídica através 
da clivagem do NPY1-36 em NPY 3-36. O peptídeo clivado estimula a acumulação lipídica através da 
activação do receptor Y2. O segundo objectivo deste trabalho consistiu na avaliação do efeito das 
gliptinas na acumulação lipídica induzida pelo NPY. Verificamos que as gliptinas reduzem esta 
acumulação lipídica induzida pelo NPY, e que este mecanismo era mediado pela acção da PKA. 
O presente estudo sugere que os inibidores selectivos da DPPIV são possíveis estratégias 
farmacológicas para prevenir o aumento do tecido adiposo sem o risco de dislipidémia.  
 
Palavras chave: Dipeptidil-peptidase IV; Gliptina; Neuropéptido Y; Adipócito; Proteína Cinase A 
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1.1 Adipose tissue 
 
The adipose tissue (AT) is a mesodermal tissue composed by several types of cells [1, 2]. One 
third are mature adipocytes whereas the other two thirds are small blood vessels, nerve tissue, 
fibroblasts and pre-adipocytes [3]. In mammals, the adipose tissue is divided in two types of tissue: 
brown adipose tissue (BAT) and white adipose tissue (WAT), the former being responsible for energy 
dissipation in the form of heat, through non-shivering thermogenesis, and the later being involved in 
energy accumulation, mainly in the form of triglycerides [2, 4, 5].   
Brown adipose tissue (BAT) contains predominantly adipocytes, which are rich in mitochondria 
and possess small multilocular lipid droplets (LD) [1, 6]. In humans, this tissue is present in neonates 
and new-born children, and is distributed through several areas of the body: pancreas, kidneys, 
adrenal glands, interscapular region (shoulder), muscles in the neck, in the axillae, trachea, 
esophagus and surrounding blood vessels [2]. Brown adipocytes main function is to transform energy 
from food into heat, through oxidative phosphorylation by uncoupling protein – 1 (UCP-1), present in 
the inner membrane of the mitochondria. In most of the tissues, where UCP-1 is absent, protons are 
pumped out of the mitochondrial matrix into the intermembrane space, generating an electrochemical 
gradient across the membrane. An ATPase would dissipate this gradient by pumping these protons 
back into the matrix, transforming ADP into ATP. However, when UCP-1 is present proton gradient is 
dissipated and ATP production is not allowed, thereby generating heat [1, 2, 4, 7, 8]. 
White adipose tissue (WAT) is found in several anatomically and physiologically distinct 
depots. There are two main white adipose tissues: the visceral and the subcutaneous adipose tissue. 
The first can be divided in omental adipose tissue, mesenteric adipose tissue and retroperitoneal 
adipose tissue [2]; whereas the second can be divided in superficial and deep subcutaneous adipose 
tissue [2]. WAT contains predominantly spherical white adipocytes that accumulate lipids, in the form of 
triglycerides, within one large lipid droplet [1, 2]. Besides accumulating triglycerides, the adipose tissue 
can also secrete molecules with endocrine, paracrine and autocrine functions [9]. 
 
 
1.2 Adipogenesis 
 
Adipogenesis is a process that corresponds to pre-adipocytes proliferation and differentiation 
into mature adipocytes, see figure 1.1 [1]. Pre-adipocytes have origin in mesenquimal stem cells (MSC) 
which, besides adipocyte differentiation, are also capable of differentiating into osteoblasts, 
chondrocytes, myoblasts and connective tissue [1]. During the differentiation process that begins after 
birth, pre-adipocytes go through four different stages before becoming mature adipocytes: i) growth 
arrest, ii) clonal expansion, iii) early differentiation and iv) terminal differentiation [1]. This differentiation 
process is only possible due to the activation of a cascade of transcription factors like peroxisome 
proliferator-activated receptor γ (PPARγ) and CCAAT enhancer binding protein (C/EBPs) family [1, 2, 10-
12]. C/EBP family is constituted by five members: C/EBPα, C/EBPβ, C/EBPδ, C/EBPγ and CHOP-10 
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[1]. Whereas some are associated with the adipogenesis process, like C/EBPα, C/EBPβ and C/EBPδ, 
others are related to the inhibition of this process, like CHOP-10 [11].  
 
 
Figure 1.1: Pre-adipocyte differentiation into mature adipocytes. 
Pre-adipocytes differentiation is induced with cAMP-elevating agents. When in the differentiated state, adipocytes 
are able to accumulate triglycerides inside lipid droplets. 
 
 
The differentiation process has been extensively studied using cell lines, like 3T3-L1, and 
primary cultures, like mouse embryo fibroblast (MEF) [12]. This process can only be initiated when pre-
adipocytes are post-confluent and growth arrested [1, 10-12]. When these two conditions are 
accomplished and the differentiation inducers are added to the in vitro culture, pre-adipocytes initiate 
the mitotic clonal expansion (MCE) with, at least, two rounds of mitosis [13].  
Immediately before the initiation of the MCE, C/EBPβ is expressed (see figure 1.2). C/EBPβ 
plays a role in two different stages of the differentiation process: it initiates the mitotic clonal expansion 
and activates the expression of C/EBPα and PPARγ [11, 13, 14].  
 
 
Figure 1.2: Progression of 3T3-L1 pre-adipocyte differentiation 
The periods of gene expression during the differentiation programme have the gene name. C/EBP, 
CCAAT/enhancer binding protein; PPARγ, peroxisome proliferator activated receptor γ. Adapted from [15]. 
 
 
When cells enter the G1 - S phase of MCE, C/EBPβ gains DNA-binding affinity by being 
phosphorylated in Thr188 and Ser184 or Thr179 by mitogen activated protein kinase (MAPK) and GSK3β, 
respectively [14]. Then, PPARγ and C/EBPα expression is induced and cells enter in the terminal 
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differentiation phase (figure 1.2). The delayed expression of these two transcription factors is critical, 
since they both have anti-mitotic activity [12, 13]. Moreover, PPARγ and C/EBPα will function together as 
transcriptional activators of a large group of genes, like those involved in lipid metabolism that confer 
the adipocyte phenotype [10, 11, 16]. In addition, they regulate each other to maintain their levels during 
and after the differentiation process [17]. 
Although PPARγ and C/EBPα act together during differentiation, PPARγ has a dominant 
action. This was observed when PPARγ null embryonic stem cells did not differentiate into adipocytes, 
whereas in C/EBPα null stem cells, PPARγ was able to promote differentiation [1, 18]. PPARγ 
expression is not restricted to induction of adipogenesis, it is also needed to maintain the differentiated 
state, otherwise adipocytes lose their ability to accumulate lipids and express their adipocyte markers 
[1]. PPARγ is only expressed two days after the beginning of differentiation [15]. Its activation is 
correlated with the loss of DNA binding activity of E2F/DP, which is involved in cell division [19]. PPARγ 
is a cis-acting element [19] that promotes gene expression via formation of a heterodimeric DNA-
binding complex with the retinoid receptor α (RXRα) [16]. To have adipogenic activity PPARγ needs 
more than being transcribed, it needs to be activated [15, 20]. Such activators can be micromolecular 
concentrations of long-chain fatty acids, like linoleic acid [19-21]; synthetic compounds, like 
thiazolidinediones (TZDs) [19, 20]; or naturally occurring eicosanoids, like prostaglandins [21]. These 
activators also differentially activate the other PPAR family members, for example, some eicosanoids, 
like 8(S)- hydroxyeicosatetraenoic acid, only activate PPARα [21]. 
PPARγ possesses two isoforms, PPARγ1 and PPARγ2, which are generated by alternative 
splicing and alternative promoter usage [1, 16]. These two isoforms are identical peptides, although 
PPARγ2 has 30 additional amino acids at the N-terminus [11]. These two isoforms are important for 
adipogenesis, although PPARγ2 plays an indispensable role [22]. When PPARγ1 and PPARγ2 
expression was abolished in 3T3-L1, these cells were unable to differentiate [22]. However, with the 
addition of exogenous PPARγ2 the differentiation was restored, whereas when the exogenous 
PPARγ1 was used no differentiation occurred [22]. In another study using PPARγ2 knockout mice, the 
same conclusion was obtained [23]. These animals showed a decrease in the overall amount of AT, 
less lipid accumulation, reduced expression of the adipogenic genes and also insulin resistance [11, 23].  
 
 
1.2.1 Adipogenic transduction pathways  
 
Some of the pre-adipocyte differentiation inducers added to the in vitro cultures are 
glucocorticoids, like dexamethasone, or insulin [15]. Both of these inducers lead to the activation of 
cAMP-responsive element-binding protein (CREB) [24], see figure 1.3. This protein is activated by the 
phosphorylation of Ser133. When phosphorylated, CREB activates the transcription of some genes like 
C/EBPβ that, at the right time, activates the transcription of other genes like PPARγ and C/EBPα [24]. 
CREBs activation can occur either through the increase in AMP cyclic (cAMP) levels that activate 
protein kinase A (PKA), which in turn activates CREB [25-27]; or through insulin pathway that activates 
extracellular signal-regulated kinase (ERK) 1/2 pathway, responsible for phosphorylating Ser133 of 
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CREB [24, 25]. Although PKA seems to have a crucial role during the beginning of the differentiation 
process, it is described that the continuous activation of PKA is responsible for inhibition of late 
differentiation. These results were obtained by the demonstration that 72 hours after the beginning of 
differentiation, cAMP levels and PKA activity are similar to basal [28]. It was also demonstrated that the 
continuous activation of PKA resulted in blockage of differentiation [28], whereas others demonstrated 
that PKA inhibitor (H-89) reduced the time span needed for full adipogenesis [29], once again, proving 
that PKA inhibits adipogenesis. 
 
 
Figure 1.3: Adipogenic transduction pathways.  
PKA activation by the increased cAMP levels leads to CREB phosphorylation. This transcription factor activates 
the transcription of C/EBPβ, which in turn activates PPARγ and C/EBPα transcription. For the successful 
progression of adipogenesis PKA needs to be inactivated. PKA, protein kinase A; CREB, cAMP-responsive 
element-binding protein; c/EBP: CCAAT/enhancer binding protein; PPARγ: peroxisome proliferator-activated 
receptor γ; 
 
 
1.3 Metabolic function 
 
WAT is the specialized tissue, of the human body, in accumulating energy in the form of 
triacylglycerols (see figure 1.4), also called neutral fats or triglycerides [30]. Each molecule of 
triacylglycerol is constituted by three molecules of esterified fatty acids (FA) and one molecule of 
glycerol [30].  
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Figure 1.4: Lipid metabolism in adipocytes. 
ACS, acyl-coenzyme A synthetase; aP2, adipocyte fatty acid binding protein; FATP, fatty acid transporter protein; 
glycerol 3-P, glycerol 3-phosphate; FFA, free fatty acids;. Adapted from [2]. 
 
 
1.3.1 Lipid droplets formation 
 
In the differentiated state, adipocytes can either synthesize FA de novo or accumulate them 
from the dietary lipids [2]. To be accumulated from dietary lipids, triacylglycerides are transported 
through the blood plasma in lipoprotein transport particles, like chylomicrons or very low density 
lipoproteins (VLDL), to the adipose tissue [31]. In order to enter the cell, they are digested by lipoprotein 
lipase (LPL) and, as fatty acids, are able to enter the cell through fatty acid transporters [2, 31]. These 
transporters can be protein CD36 (human homologue to the murine fatty acid translocase, (FAT), fatty 
acid transport protein (FATP) and fatty acid binding protein (FABPpm) [31]. When in the cytoplasm, FA 
are carried out by cytoplasmatic binding proteins, like aP2, to acyl CoA synthase reaction site [31]. This 
enzyme catalyses the reaction of FA with an acetyl-CoA, originating fatty acyl-CoA [32]. Afterwards, this 
molecule reacts with glycerol-3-P, which is produced during glycolysis, originating the triglyceride 
molecule [32]. During the fatty acids de novo synthesis, the acyl-CoA molecule comes from an acetyl-
CoA molecule that was produced from pyruvate in the glycolytic pathway, inside the mitochondria [30]. 
This acyl-CoA molecule, together with a glycerol-3-P molecule gives rise to a triglyceride molecule [30]. 
These triglyceride molecules (TAG) are kept inside lipid droplets protected by proteins called perilipin 
[33].  
 
 
1.3.1.1 Perilipin 
 
Perilipin belongs to a family called PAT family where are also included adipose differentiation-
related protein (ADRP) and TIP-47 [34]. Perilipin is expressed in differentiated adipocytes and, under 
non-stimulated conditions, it protects lipid droplets from the action of lipases and therefore from 
lipolysis [35]. In pre-adipocytes or in differentiating fibroblasts the small lipid droplets are protected by 
ADRP that is replaced by perilipin when adipocytes become differentiated [33]. Perilipin has two 
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isoforms: perilipin A and perilipin B, that result from mRNA splicing of a single perilipin gene [33]. 
Perilipin A has six phosphorylation sites, whereas perilipin B only has three phosphorylation sites [34]. 
Perilipin A is found in the outer surface of the lipid droplet and is a critical component of a scaffold that 
stabilizes the lipid droplet [35]. This distribution at the surface of the lipid droplets is the main 
mechanism that prevents lipases from reaching TAG, thus inhibiting lipolysis [35]. 
 
 
1.3.2 Lipolysis 
 
Lipolysis is the controlled process of hydrolysis of TAG, with consequent release of three fatty 
acid molecules and one glycerol [33, 36]. This process is triggered by hormonal stimulus, like 
catecholamines; by agents that elevate cAMP levels, like forskolin; or by cAMP analogous [33, 37]. 
When a catecholamine binds its β-adrenergic receptor, occurs the activation of a stimulatory G-protein 
(Gαs) that activates adenyl cyclase [33, 37]. Consequently, cAMP levels rise and activate the regulatory 
subunits of PKA [33, 37]. When in its active form, PKA phosphorylates the two key enzymes of the 
lipolysis process: perilipin and hormone sensitive lipase (HSL) (see figure 1.5) [33, 37]. As described 
above, perilipin plays a crucial role in preventing lipolysis [33, 35, 37]. However, it is also a crucial enzyme 
in “allowing” lipolysis [33, 35]. When this enzyme is not phosphorylated it is anchored to the lipid droplet 
and contributing to the barrier formation against the action of lipases like HSL. However, when it is 
phosphorylated by PKA, perilipin plays a different role [35]. When PKA phosphorylates these two 
proteins, perilipin changes its conformation allowing HSL to translocate to the surface of the lipid 
droplet [33]. While leaving the surface of the lipid droplet, perilipin facilitates the interaction between 
HSL and the lipid droplet [35]. HSL is a serine hydrolase regulated by reversible phosphorylation, 
whose metabolic function is to catalyse hormone-stimulated lipolysis [36]. This enzyme is present in the 
cytosol of adipocytes in its unphosphorylated form [33, 36]. Although HSL has several phosphorylation 
sites, the crucial for its activation as a lipase are Ser659 and Ser660 [33, 36]. It is important to note that the 
perilipin-HSL interaction is required, otherwise HSL alone is not able to reach the lipid droplet surface 
[33] and to initiate the hydrolysis of the ester bonds. Meanwhile, perilipin leaves the surface of the lipid 
droplet and its lysosomal degradation is started [38]. Because of this degradation it is possible to 
observe a decrease in perilipin levels with the concomitant increase of lipolysis [38]. 
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Figure 1.5: Lipolysis transduction pathways in a human adipocyte. 
Lipolytic pathway is described. PKA, protein kinase A; HSL, hormone sensitive lipase; FFA, free fatty acid; P- 
phosphorylated; PLP, phosphorylated perilipin. Adapted from [37]. 
 
 
1.4 Endocrine function  
 
Besides being a specialized organ in accumulating energy, the adipose tissue is also seen as 
an endocrine, autocrine and paracrine organ [9]. Such action is accomplished by the production of 
several molecules, also called adipocytokines or adipokines [39], whose actions influence not only the 
metabolic activity of the adipose tissue but also other tissues like the brain, muscles and liver [9, 40]. As 
outlined in table 1, adipocytokines have effects on multiple biological systems like energy homeostasis 
(lipid and carbohydrate metabolism, appetite, thermogenesis), immune system, reproductive function, 
hemostasia/coagulation, blood pressure and angiogenesis, see revision [41]. As referred before, the 
adipose tissue possesses other cell types besides adipocytes that can be the source of some of these 
adipocytokines [39]. 
Some of these molecules are leptin, adiponectin, visfatin, omentin, resistin, retinol-binding 
protein 4 (RBP 4), tumor necrosis factor – α (TNF-α), Interleukin-6 (IL-6) and other cytokines, see 
revision [42]. The former four molecules have anti-diabetic functions, while the later four molecules tend 
to raise blood glucose levels (see figure 1.6) [40, 43].  
Leptin was the first adipokine to be discovered and is secreted almost exclusively by fat, more 
specifically by adipocytes [40]. Leptin has a wide spectrum of endocrine and paracrine functions that 
include appetite regulation, modulation of hepatic and adipose tissue-related insulin secretion and 
activity, modulation of steroid production in the ovaries and adrenal cortex, effects on reproductive 
physiology, and in hematopoietic and immune development, see revision [39]. Leptin acts through a 
leptin receptor that is highly expressed in the mediobasal hypothalamus, more specifically in the 
arcuate nucleus, ventromedial nucleus and dorsomedial nucleus, see revision [42]. When activated, 
leptin receptor represses orexigenic pathways, like those involving neuropeptide Y (NPY), and induces 
anorexigenic pathways, for example, those involving proopiomelanocortin (POMC) [40]. These actions 
include repressing of food intake, increasing energy expenditure and anti-hyperglycaemic actions that 
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result in improvement of insulin sensitivity in muscle and liver [40]. Animals and humans with mutations 
in lepin or in leptin receptor became obese, showing the importance of this adipokine in regulating 
food intake and energy expenditure [6]. Morrison et al., (2005) demonstrated that this effect of leptin 
mutations is due to increased NPY expression in the arcuate nucleus, which leads to increased food 
intake and decreased energy expenditure [44, 45]. In the same study, it was also observed that when 
leptin was injected in leptin deficient mice, NPY mRNA levels were decreased in the arcuate nucleus 
[44]. These results suggest that leptin action might also be through modulation of other peptides 
secretion [44]. 
 
 
Figure 1.6: Examples of molecules secreted by the adipose tissue with varied effect  
Leptin, adiponectin, visfatin and omentin are adipokines with anti-hyperglycaemic effects. Resistin, tumour 
necrosis factor-α (TNFα), interleukin 6 (IL6) and Retinol-binding protein 4 (RBP4) are molecules with pro-
hyperglycaemic activity. Neuropeptide Y (NPY) and dipeptidyl-peptidase IV (DPPIV) with adipogenic activity. 
Adapted from [40]. 
 
 
Adiponectin is a 30 kDa protein also known as apM1, GBP28, AdipoQ and ACRP30 [40]. It 
has an amino-terminal collagen-like domain and a carboxyl-terminal globular domain that mediates 
multimerization [40]. Adiponectin is specifically expressed in differentiated adipocytes and suffers 
posttranslational modification [46]. This adipokine circulates as a trimer, hexamer or as a higher-order 
multimer that circulates in plasma in such high concentrations that account for 0.01% of all plasma 
protein [40]. Adiponectin has two different receptors, AdipoR1 and AdipoR2, being the former primarily 
expressed in muscles, and the latter primarily expressed in the liver [41]. Adiponectin effects depend on 
circulating levels, on the properties of the different adiponectin isoforms and also on tissue specific 
expression of adiponectin receptors [46]. Nevertheless, there are some general functions associated 
with adiponectin, like anti-diabetic and anti-inflammatory functions [47]. The anti-diabetic functions are 
related with the increased levels of adiponectin when TZDs are administered, resulting in improved 
insulin sensitivity [40].  
Visfatin is produced by visceral adipose tissue and was firstly identified in immune cells as a 
pre-B-cell colony-enhanced factor (PBEF) [40]. It can directly bind and activate the insulin receptor 
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which results in an enhanced glucose uptake [43]. Because its circulating levels are less than 10% 
compared to insulin levels, these two molecules do not compete for receptor binding [40]. A recent 
article suggested that visfatin not only activates the insulin receptor, but also regulates insulin 
secretion and several β-cell function-associated genes in mouse [48].  
Omentin is secreted by stromal-vascular cells present in visceral fat [32]. It acts as an insulin 
sensitizer rather than insulin mimetic, resulting on positive effects in glucose uptake [32]. In humans 
and macaques it is produced in high quantities, but in mice no production was detected [40]. Although 
omentin levels decrease with obesity and insulin resistance, the mechanism of action is still unknown 
[43]. 
Retinol-binding protein 4 (RBP4) is a member of the lipocalin superfamily and its expression 
is regulated by changes in the glucose transporter type 4 (GLUT4) [40]. High serum levels are 
associated with insulin resistance in humans with obesity, type 2 diabetes mellitus and in lean non-
diabetic people with family history of type 2 diabetes mellitus. RBP4 overexpression in mice, also 
resulted in impaired insulin action both in muscle and liver [32]. 
The adipose tissue also produces some cytokines, like interleukin 6 (IL-6), and tumour-
necrosis factor α (TNFα) [40]. Although TNFα is secreted in the adipose tissue, it is not secreted by 
adipocytes, but by macrophages that surround adipose tissue [46]. This adipokine also plays a role in 
glucose homeostasis, by decreasing insulin sensitivity [39]. Its levels are elevated in obese conditions 
and in other insulin-resistant cases [39]. Moreover, when TNFα expression was blocked, insulin 
sensitivity was restored, both in vitro and in vivo [40]. On the other hand, IL-6 is produced by adipocytes 
and circulates in multiple glycosylated forms [46]. Its expression and circulating levels are positively 
correlated with obesity, glucose intolerance and insulin resistance [39]. When peripherally 
administrated, IL-6 reduces the expression of insulin receptor signalling components, decreases 
adiponectin secretion and inhibits adipogenesis [46].  
Resistin, also known as FIZZ3, is a small inflammatory molecule with hyperglycaemic action 
[40]. Although some authors indicate that it is secreted by adipocytes [49], it is still controversial since 
new data suggests that resistin is secreted by macrophages [50] or other stromal cells present in the 
adipose tissue [51]. Resistin circulates in the plasma in several multimeric forms, but are those with 
small weight that seem to have an effect at the cellular level [6]. Resistin reduces glucose uptake in 
muscles and is repressed by TZDs [6]. This molecule can also modulate the secretion of other 
molecules, such as NPY [52]. This was observed when resistin was centrally administered to mice, 
resulting in increased NPY production in the arcuate nucleus [52]. Resistin effects on glucose 
production were blocked in mice lacking NPY [52]. 
In conclusion, the adipose tissue has very important actions in regulating body homeostasis. 
Not only by accumulating energy but also by signalling to the brain when food intake is needed and 
when is not, through the production of peptides, like NPY [53]. Adipokines also support the other tissues 
with all the energy that they need to work properly [32]. 
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Table 1: Examples of some factors secreted in the adipose tissue and respective function [6, 32]. 
Adipokine Biological effect 
Leptin Signals to the CNS about the body’s energy stocks 
Adiponectin Increases sensitivity to insulin; antiinflammatory; attenuates the 
progression of atherosclerosis 
Visfatin Insulin-mimetic; predominantly produced by visceral fat 
Omentin Enhances insulin-stimulated signals and glucose uptake but it is not insulin-mimetic 
TNFα  Lipolytic; increases energy consumption; reduces sensitivity to insulin 
IL-6 Proinflammatory, lipolytic, reduces sensitivity to insulin 
Resistin Increases insulin resistance 
RBP4 Reduces insulin sensitivity; Impaires insulin action in the muscle 
 
 
1.5 Dipeptidyl peptidase IV 
 
1.5.1 Structure and localization 
 
Dipeptidyl peptidase IV (E.C. 3.4.14.5) is a 110 kDa glycoprotein, also known as DPPIV or 
CD26 [5]. This enzyme is a ubiquitous and multifunctional molecule that exists in both soluble and 
membrane bound form. DPPIV is also a homodimer but it functions only while in its dimer form [5, 54-57]. 
In its membrane form, DPPIV has three regions: a cytoplasmatic domain with 6-amino acids, a 
hydrophobic transmembranar region with 22-amino acids and an extracellular domain with 738-amino 
acids [56]. When the hydrophobic N-terminal domain is cleaved [58] by chymotrypsin-like or pepsin-like 
enzymes [59], DPPIV is released into the plasma, becoming soluble, though maintaining both substrate 
specificity and susceptibility to inhibitors [57]. While in its soluble form, DPPIV can be found not only in 
the blood plasma, but also in the cerebrospinal fluid and semen [60, 61]. As a membrane protein, it is 
widely expressed in various tissues and organs, including the exocrine pancreas [62], kidneys [63], 
gastrointestinal tract [64], thymus [65], lymph nodes [66], uterus [67], placenta, prostate [68], adrenal [69], 
sweat [70], salivary and mammary glands [70], endothelia of spleen [71], lungs [63], brain [69], and vessels 
supplying the liver [61, 72, 73]. In addition, this enzyme is also present in lymphocytes, as the cell-surface 
CD26 T-cell-activating antigen and also as a membrane antigen of both Natural Killer (NK) and B cells 
[61, 73-75].  
 
 
1.5.2 Function and substrates 
 
DPPIV is a multifunctional protein involved in several processes like cell growth [76] and 
differentiation [77], adhesion [60], immunomodulation [78], metabolism [79], endocrinology, cancer biology 
and apoptosis [68, 80]. In order to accomplish these processes, DPPIV has three mechanisms of action 
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[78]: (i) cell-extracellular matrix interactions [60] (ii) co-stimulatory role in the immune system [5, 60, 78, 81, 82] 
and (iii) cleavage of biologically active molecules [60]. 
The extracellular matrix interactions are characterized by the ability of this enzyme to bind 
some ligands, like adenosine deaminase (ADA), kidney Na+/H+ ion exchanger 3 [60, 78]. DPPIV is also 
able to bind fibronectin and collagen and the association of DPPIV with fibronectin, in lung cancer 
cells, is responsible for growth arrest of these cells [83]. In cancer cells DPPIV has anti-proliferative and 
anti-oncogenic effects and is down-regulated [68, 78]. Although it is not known the exact mechanism of 
action, DPPIV down-regulation will create a proteolytic imbalance of the extracellular regulatory 
proteins within the tumour environment [68, 69, 84] which is characteristic of malignancy [78]. 
DPPIV also has a very important role in the immune system. This enzyme is not only able to 
regulate multiple T-cell functions, like maturation, activation, migration and interaction with antigen-
presenting cells; but is also able to regulate proliferation and activation of B-cells and NK cells [60, 78]. 
Furthermore, DPPIV can also cleave several immunoregulating cytokines [78]. When in the surface of 
T-cells, the signal transduced by CD26 co-stimulates the T-cell receptor CD3 pathways, leading to T-
cell activation [85]. CD26 activation occurs through caveolin-1 or CD45 and leads to tyrosine 
phosphorylation which increases phosphorylation of several molecules like p56lkc, p59fyn, zeta 
associated protein-tyrosine kinase of 70000MW (ZAP-70) and MAPK [5, 60, 78, 86]. Studies also showed 
that in some autoimmune diseases, like Multiple Sclerosis and Arthritis, the CD26 expression is up-
regulated in T-cells, B-cells and NK-cells [5, 78]. Taking all together, it can be concluded that DPPIV 
inhibitors are useful tools for immune suppression in autoimmune diseases [5, 78, 82]. 
The DPPIV ability to cleave molecules is restricted to those enzymes having a Xaa-Pro or 
Xaa-Ala dipeptides, from the N-terminus of polypeptides (where Xaa is any amino acid except Pro) [5, 
54, 61, 74]. These active molecules, as outlined in table 2, include a variety of neuropeptides, chemokines 
and circulating hormones, among others [54, 56, 61]. When cleaved by DPPIV, these molecules can either 
be inactivated, like gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP1); their receptor 
specificity altered, as NPY and peptide YY (PYY); or their activity reduced, like monokine induced by 
gamma interferon (MIG) [61, 78, 87]. 
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Table 2: DPPIV substrates [61, 78, 87, 88] 
Neuropeptides Neuropeptide Y 
	  
Endomorphin 
	  
Substance P 
	  
Beta-casomorphin 
	  
Pituitary adenylate-cyclase-activating polypeptide (PACAP) 
  Vasoactive intestinal peptide (VIP) 
Other regulatory 
peptides Gastric inhibitory peptide (GIP) 
	  
Gastrin-releasing peptide (GRP) 
	  
Glucagon-like peptide 1 (GLP-1) 
	  
Glucagon-like peptide 2 
	  
Growth-hormone releasing factor (GHRF) 
  Peptide YY (1-26) 
Chemokines Eotaxin 
	  
Monokine induced by gamma Interferon (MIG) 
	  
Interferon-inducible protein-10 
	  
Chemokine lingand 5 (RANTES) 
	  
Macrophage-derived chemokine 
	  
Macrophage inflammatory protein-1beta 
	  	   Monocyte chemotatic proteins 1-3	   
 
 
Some of these substrates have different functions, depending on the tissue where they are 
produced and on the presence of their receptors [87]. The adipose tissue, has receptors for GLP-1 [89], 
GIP [90], Substance P (SP) [91-93], Pituitary adenylate-cyclase-activating polypeptide (PACAP) and NPY 
[94]. 
 
 
1.5.2.1 DPPIV substrates and their functions in the adipose tissue 
 
GLP-1 is a peptide released by the enteroendocrine cells (L-cells), in the gut [95, 96]. Besides 
stimulating the adipose tissue to produce leptin, this peptide also decreases fat storage [89, 97]. GLP-1 
enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential 
extrapancreatic sites of GLP-1 action [98]. This process is not accomplished through lipolysis, but via 
direct modulation of adipocyte metabolism [97]. Nevertheless, this ability to modulate the adipocyte 
metabolism is not present in obese condition, suggesting an obesity-induced adipocyte resistance to 
GLP-1 [97]. 
GIP is synthesized and secreted from K cells in the intestinal epithelium [99]. It has been shown 
that this peptide has a direct effect on adipocytes by dose dependently stimulating lipoprotein lipase 
activity and also fatty acid synthesis [90]. In addition, mice lacking GIP receptor (GIPr (-/-)) fed with a 
high fat diet were clearly protected from both obesity and insulin resistance [100]. 
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SP is released from the enteric nerves, sensory neurons and also from inflammatory cells of 
the lamina propria during intestinal inflammation [91]. This peptide also plays a role in the adipose 
tissue by increasing pre-adipocyte viability and proliferation, and also by decreasing apoptosis [91]. 
PACAP is released upon stimulation of the parasympathetic nerves [101]. By alternative splicing 
this peptide can be released in two forms, PACAP38 and PACAP27, having the former more affinity to 
DPPIV [87]. PACAP function in the adipose tissue depends on the presence of insulin, i.e., if insulin is 
present, this peptide potentiates glucose uptake which leads to lipogenesis; if insulin is absent, 
PACAP becomes lipolytic [94]. 
NPY is synthesized both in the hypothalamus and in the adipose tissue [102, 103]. In the adipose 
tissue, NPY increases expression and activity of lipoprotein lipase, which leads to increased 
lipogenesis [102]. It also has a very strong anti-lipolytic effect, resulting in increased weight gain [102, 104]. 
The effect of NPY in the adipose tissue will be discussed later on section 1.6.3. 
 
 
1.6 Neuropeptide Y 
 
NPY is a 36 amino acid peptide amidated in the C-terminal [105]. It belongs to the same family 
as peptide YY (PYY) and pancreatic polypeptide (PP), with whom shares 70 and 50% of sequence 
identity, respectively [105]. This peptide was first discovered in the porcine brain [53] and is the most 
abundant peptide in the human brain and very well conserved among species [106]. The NPY gene is 
located in the human chromosome 7 and is expressed mainly in the hypothalamus, more specifically, 
in the paraventricular nucleus, arcuate nucleus, suprachiasmatic nucleus, median eminence and 
dorsomedial nucleus [53]. In the sympathetic neurons, NPY is colocalized with norepinephrine [106]. 
Besides neuron cells, there are also other cells able to secrete NPY like, for example, liver, heart, 
spleen, endothelial cells of blood vessels and adipose tissue [53, 103]. 
NPY is a neurotransmitter involved in the regulation of several actions like, control of food 
intake, regulating the activity of neuroendocrine axes under poor metabolic conditions, 
vasoconstrictive actions, cardiovascular regulation, blood pressure, catecholamine secretion, energy 
homeostasis, neuroendrocrine regulation, memory processing, anxiety, body temperature, 
lipogenesis, among others [53, 105-107]. 
 
 
1.6.1 NPY synthesis 
 
When synthesized, NPY is a precursor peptide of 97 amino acids: preproNPY that, after 
cleavage, loses its signal sequence, see figure 1.7 [53]. This new peptide, with 69 amino acids, is 
further converted into NPY1-39 and C-flanking peptide of NPY (CPON) (30 amino acids) by a group of 
enzymes called pro-converting enzymes [106]. Afterwards, a carboxypeptidase-like enzyme cleaves two 
more amino acids giving rise to NPY1-37, which is amidated in the C-terminal, by a peptidyl-glycine-α-
amidating monooxygenase, losing one amino acid and becoming NPY1-36 [106]. Although this peptide is 
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already in its biologically active form it can be further be cleaved by aminopeptidase P or DPPIV, like 
described above [106]. 
 
 
Figure 1.7: Synthesis and post-transactional modifications of neuropeptide Y. 
Adapted from [106]. 
 
 
1.6.2 NPY receptors 
 
NPY acts through six G-protein-coupled receptors: Y1, Y2, Y3, Y4, Y5 and y6 [106]. This type of 
receptor is associated with a seven-transmembrane-helix (7TM) receptors (see figure 1.8) that, when 
activated, suffers a conformational change which in turn activates a G protein [30]. NPY receptors are 
Gi/Go coupled receptors that when activated inhibit the action of adenyl cyclase [108]. This action 
results in decreased cAMP levels that in turn prevent PKA activation [30]. Besides decreasing cAMP 
levels, NPY receptors are also able to increase intracellular calcium levels [108, 109]. 
 
 
Figure 1.8: Representation of the amino acid sequence of the G-protein coupled Y1 receptor 
[110]. 
 
 
PreproNPY
ProNPY
NPY1-39
NPY1-37
NPY1-36
NPY3-36
Signal peptidase
Prohormone convertase
Carboxy peptidase
Dipeptidyl-peptidase IV
1 97
Peptidylglycine α-amidating monooxygenase
1
1
1
1
3
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37
36
NH2
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1.6.2.1 NPY Y1 receptor 
 
NPY Y1 receptor gene is localized in the chromosome 4q(31,3-32) and it is expressed in the 
brain, heart, kidneys and gastrointestinal tract, see revision [106]. NPY binding activity to this receptor is 
largely impaired when enzymes, like DPPIV, cleave the NPY N-terminal peptides [53]. However, when 
the C-terminal peptides are modified, NPY retains its full binding capacity to Y1 receptor, suggesting 
that this neurotransmitter binds this receptor through its N-terminal region [53]. The main effects of 
NPY, mediated by Y1 are vasoconstriction [53], increased appetite [111], decreased depression [112] and 
anxiety [106], activation of the neuroendocrine axes [106], and proliferation of smooth muscle cells [113], 
progenitor cells of the hippocampus [114], pancreatic β cells [115], Muller cells [116] and tumour cells [117]. 
 
 
1.6.2.2 NPY Y2 receptor 
 
The NPY Y2 receptor is located in the chromosome 4q31, close to the  NPY Y1 and Y5 receptor 
locus [106]. Its expression is found in the central and peripheral nervous system, gut, certain blood 
vessels and adipose tissue, see revision [53]. This receptor does not require the NPY N-terminal 
sequence, since it binds NPY3-36 and NPY1-36 with the same affinity [53]. NPY Y2 receptor also plays a 
role in control of appetite [118] and angiogenesis [113], neurotransmitter release [106]. 
 
 
1.6.2.3 NPY Y3 receptor 
 
NPY Y3 receptor is called the NPY preferring receptor since it shows 10-fold higher affinity for 
NPY than for PYY [53]. Although it has never been cloned nor well characterized [106], it can be found in 
several peripheral tissues, like rat superior cervical ganglia sympathetic neurons [119], rat cardiac 
ventricular membranes [106] and rat distal colon [120]. In human adrenal medulla mediates NPY-induced 
secretion of catecholamines [121]. 
 
 
1.6.2.4 NPY Y4 receptor 
 
NPY Y4 receptor is located in the chromosome 10q 11-12 [106] and was first identified as a PP 
receptor [53], because it binds PP with higher affinity than NPY or PYY [122]. This receptor is mainly 
expressed in the colon, small intestine, prostate [106], pancreas, smooth muscle cells and in various 
regions of the brain, like hypothalamus [123-125]. Its affinity to NPY is only moderate, however PP is the 
primary endogenous ligand. Therefore, PP effects like inhibition of exocrine pancreatic secretion or 
induction of gall bladder relaxation, might occur through this receptor [53]. 
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1.6.2.5 NPY Y5 receptor 
 
NPY Y5 receptor gene is located in chromosome 4q32, in the same locus as NPY Y1 receptor, 
although their transcription is in opposite directions [106]. NPY Y5 receptor is activated by NPY, PYY, 
PYY analogs and fragments of peptides, such as NPY3-36 and PYY3-36 [126]. It is mainly expressed in the 
hypothalamus, where it stimulates the appetite [127]; and, at the peripheral level, is present in the 
intestine, ovary, testis, prostate, spleen, pancreas, kidney, skeletal muscle, liver, placenta and heart, 
see revision [53]. 
 
 
1.6.2.6 NPY y6 receptor 
 
NPY y6 receptor is localized in the chromosome 5q31 [106] and, like NPY Y4 receptor, shows 
higher affinity to PP than to NPY or PYY [128, 129]. This receptor is present in mice, rabbits, primates and 
humans, although its physiological action is not yet known [130-132]. y6 receptor mRNA was also 
detected in several tissues like hypothalamus, hippocampus, gut and adrenal glands of rabbits; and 
also in skeletal muscle and hypothalamus of humans [130, 131, 133]. 
 
 
1.6.3 NPY and NPY receptors in the adipose tissue 
 
The presence of NPY and its receptors in several tissues and the important actions played by 
this neuropeptide, raised the question of whether NPY would also play a role in the adipose tissue. 
When synthesized in the hypothalamus, NPY has a very potent orexigenic action [134]. When centrally 
administered, NPY causes a strong increase on food intake (hyperphagia) and a decrease on energy 
expenditure, resulting in weight gain [135]. Recent studies showed that both NPY and some of its 
receptors are synthesized in the human [135], pig [136], mouse [94] and rat [135] adipose tissue as well as in 
a murine pre-adipocyte cell line (3T3-L1) [94], suggesting that this peptide might play a role directly in 
the adipose cells.  
 
 
1.6.3.1 NPY role on lipid accumulation 
 
NPY expression levels are not always constant and there are many factors influencing NPY 
expression levels [106]. Nevertheless, it is also important to understand in which situations NPY 
expression levels are upregulated in the adipose tissue. During the early life of a programmed rat 
model of increased adiposity, scientists observed that NPY levels were 6-fold higher [103]. In the same 
study using as animal model the obese Zucker rats, NPY mRNA expression levels were also 
increased 2-fold [103]. And, because insulin stimulates NPY secretion, in cases of hyperinsulinemia, 
NPY levels should also be elevated [102]. Furthermore, it was also described that NPY has a direct 
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effect on adipocytes by promoting cell proliferation, lipid accumulation and cell differentiation in a 3T3-
L1 cell line [94, 103]. Moreover, when NPY was subcutaneously applied to mice and monkeys, it 
stimulated growth of the adipose tissue [137]. Although it is still not established if these effects in the 
adipose tissue are mediated by Y1 or Y2 receptor [103, 137], it is already accepted that NPY up-regulates 
both lipoprotein lipase and fatty acid synthase expression and activity, two key enzymes in lipogenesis 
[94, 102].  
Apart from playing a role in lipogenesis, NPY also has a role in lipolysis [94, 104]. Like it was 
described above, for lipolysis to occur, cAMP levels must be elevated [34]. However, when NPY 
receptors are activated, cAMP levels decrease [108]. In fact, this was observed in primary human 
adipocytes where NPY inhibited lipolysis [94]. This effect was confirmed by adding a NPY antagonist 
(S.A.0204), resulting in increased lipolysis and consequently the total lipid content decreased [107]. 
Other study also showed that NPY injection in rats or mice, not only stimulated food intake, but also 
inhibited lipolysis [53]. In addition, it was also shown that under hyperinsulinemic conditions, NPY 
increased adipocytes size [102]. The NPY receptor that mediates this action is still controversial. Some 
groups indicate that NPY’s anti-lipolytic effect is through Y1 receptor [135, 138], proven by binding studies 
and using antagonists [102, 106, 135, 138, 139]; and others showed evidences of the activation of Y2 receptors 
[94]. Nevertheless, it seems that in rat adipose tissue there is a dual control through Y1 and Y2 [135]. Y5 
involvement was also proposed since the addition of Y5 receptor agonists stimulated the accumulation 
of triglycerides by inhibiting lipolysis [140, 141]. 
 
 
1.7 Dipeptidyl peptidase IV inhibitors 
 
Dipeptidyl peptidase IV  (DPPIV) inhibitors are a class of drugs mainly used in patients with 
Type 2 Diabetes Mellitus (T2DM) [61]. This disease is characterized by high circulating glucose levels 
that resulted from insulin resistance and further impaired insulin secretion by the β-cells in pancreas 
[142, 143].  
The main target of DPPIV inhibitors is to increase the half life of some insulin-stimulating 
hormones, like, GLP-1 and GIP [74]. Inhibition of plasma DPPIV leads to enhanced endogenous GLP-1 
and GIP activity, which ultimately results in the potentiation of insulin secretion by pancreatic β -cells 
and subsequent lowering of blood glucose levels, HbA1c, glucagon secretion and liver glucose 
production [61, 81, 142]. In addition, GLP-1 and GIP have beneficial effects on pancreatic β-cells, including 
increased β-cell survival and expansion of β-cell mass [61].  
These inhibitors are associated with low risk of hypoglycaemia and weight loss or weight 
neutrality [144]. DPPIV knockout mice, besides being healthy, have resistance to hepatic lipid 
accumulation when fed with a high fat diet [61]. In addition, investigators suggested that inhibiting 
DPPIV the circulating free fatty acids were prevented from rising not due to inhibition of FA 
mobilization but because FA oxidation was increased [144-146]. Moreover, it was also observed that, by 
inhibiting DPPIV, both apolipoprotein and chylomicron lipid levels were decreased, suggesting that 
these inhibitors also might inhibit intestinal fat extraction [144, 146]. 
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Several inhibitors can be already found in the market and some are still waiting for Food and 
Drug Administration (FDA) approval (see table 3). 
Because until 2010 Vildagliptin, Sitagliptin and Saxaglipin were the only three gliptins 
commercialized in Europe and, except from vildagliptin, also approved by FDA, our work will focus on 
them. 
 
 
1.7.1 Vildagliptin 
 
Vildagliptin, also known as LAF237 or Galvus®, is commercialized by Novartis and is a 
selective inhibitor of DPPIV [147]. This drug has a half maximal inhibitory concentration (IC50) of 3,5 nM 
[61, 148] and specificity (Ki) of 17 nM [148]. It is normally taken by T2DM patients at a dose of 100 mg, 
being rapidly absorbed with 85 % of bioavailability [148]. When in the plasma, its half-life is 90 minutes 
[148] whereas when in the enzyme-inhibitor complex is 135 minutes [143]. 15-30 minutes after oral 
administration, DPPIV is inhibited by almost 100 % and maintains more than 80 % of inhibition for 16 
hours [147]. This enzyme-inhibitor complex is covalently bound and is reversible [61, 148, 149]. In addition, 
vildagliptin behaves as a slow-binding inhibitor with slow decline in potency with time, which suggests 
that it acts as a tight-binding inhibitor [143]. Nevertheless, this inhibitor has some adverse effects like 
increased risk of infection (nasopharyngitis and urinary tract infection), dizziness and nausea [150]. 
 
 
1.7.2 Sitagliptin 
 
Sitagliptin (MK-0431, Januvia®) is produced by Merck and, like vildagliptin, is a selective 
inhibitor for DPPIV [147] with an IC50 of 18 nM and a Ki of 9 nM [61, 148]. Although its plasma half-life is 2-
fold higher than vildagliptin [61], the enzyme-inhibitor complex only lasts for 80 minutes [143]. Sitagliptin’s 
selectivity is also higher than vildagliptin’s, however no differences on side effects were found, 
suggesting that this difference is not of great importance [61]. The recommended dose is 100 mg once 
daily [150] and DPPIV plasma activity was also inhibited almost 100 % after 15-30 minutes of oral 
administration and lasted superior to 80 % for more than 16 hours [147]. It has renal excretion, where 
approximately 80 % of the oral dose is excreted unchanged in the urine [150]. Sitagliptin has a different 
kind of action, since it is a non-covalent reversible inhibitor [61, 148, 149]. Nevertheless, this gliptin is also 
a slow binding inhibitor with slow decline in potency with time [143]. 
When administered to patients with T2DM it showed effective glycaemic control, both in 
fasting and post-prandial conditions [148]. In addition, sitagliptin decreased adipocyte size and 
enhanced post-prandial lipid mobilization and oxidation [151]. The adverse effects observed were 
elevated risk of infection (nasopharigitis and urinary tract), headache and upper respiratory tract 
infection [150]. 
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1.7.3 Saxagliptin 
 
Saxagliptin (BMS-477118, Onglyza®) is produced by Bristol-Myers Squib/Astra 
Zeneca/Otsuka Pharma and has an IC50 of 3.37 nM, a Ki of 0.6 nM [148] and the enzyme-inhibitor 
complex has a half-life of 713 minutes [143]. This inhibitor is also highly selective for DPPIV and the 
daily dose taken by patients with T2DM is 5 mg [150]. Saxagliptin is well absorbed, has a low plasma 
protein binding and is metabolized in vivo to form an active metabolite that is 2-fold less potent than 
the parent molecule [152]. Saxagliptin is also covalently bound to DPPIV in a reversible way [148, 152]. 
Like vildagliptin and sitagliptin, saxagliptin also behaves as a slow-binding inhibitor with a slow decline 
in potency with time [143]. This gliptin has a dissociation constant 5-8 fold slower than the dissociation 
constants of the other inhibitors [143]. Likewise, saxagliptin showed the longer duration of action and the 
greatest potency of all DPPIV inhibitors [143]. 
When administrated to T2DM patients, it significantly improved glycaemic control by 
decreasing fasting plasma glucose and post-prandial glucose, when added with sulphonylureas or 
TZDs [148]. This inhibitor also has adverse effects like arthralgia, cough, headache, nasopharingitis, 
nausea, upper respiratory tract infection and urinary tract infection [150].  
One of the disadvantages pointed to this type of inhibitors, is its specificity among DPPIV 
family members. However the IC50 or Ki needed to inhibit these other members are much higher than 
those used in therapy [148].  
 
Table 3: Examples of DPP IV inhibitors [5, 61, 73, 74, 81, 142, 149, 150, 153-156] 
Name Type of Action Status 
Vildagliptin (LAF-237) Covalently bound, Reversible inhibitor Approved in Europe; Approved in Portugal 
Sitagliptin (MK-0431) Non-Covalently bound, Reversible inhibitor Approved by FDA in 2006; Approved in Portugal 
Saxagliptin (BMS-477118) Covalently bound,Reversible inhibitor Approved by FDA in 2009; Approved in Portugal 
Linagliptin (BI-1356) Reversible inhibitor Approved by FDA in 2011 
Denagliptin (GSK823093C) - Discontinued 
Alogliptin (SYR-322) Reversible inhibitor Rejected by FDA in 2009 
Dutogliptin (PHX-1149) Reversible inhibitor Phase II trials 
Carmegliptin (R-1579) Reversible inhibitor Phase II trials completed 
Melogliptin (GRC8200) - - 
Isoleucine thiazolidide (P32/98) Non-Covalently bound, Reversible inhibitor Phase II trials 
NVP-DPP728 Covalently bound, Reversible inhibitor Discontinued 
PSN-9301 Reversible inhibitor Phase II trials 
NN-7201 Reversible inhibitor Phase I trials 
ALS 2-0426 - Phase I trials 
Aminomethylpyridine (R1438) Reversible inhibitor Phase III trials 
ABT-279 - Phase II trials 
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1.8 DPPIV and gliptins in the adipose tissue 
 
Inhibition of DPPIV became one of the most promising treatments for T2DM mainly because it 
lowers glucose levels by regulating GLP-1 and GIP [157]. Later it was discovered that not only this 
enzyme is also secreted in the adipose tissue [158], but it might also play a role in the modulation of this 
tissue [74, 158]. T2DM patients treated with sitagliptin have a decrease in the hepatic input of non-
esterified fatty acids that was correlated with lower fat depots and a decrease in adipocytes size [151]. 
These effects were due to an increase in post-prandial lipid mobilization and oxidation [146, 151]. During 
clinical trials with vildagliptin, sitagliptin and saxagliptin, no significant changes in body weight were 
observed [144]. However, vildagliptin treatment also showed an increase in post-prandial lactate and 
glycerol in the adipose tissue, together with a decrease in pyruvate and lactate in skeletal muscle [144]. 
Taking it together, vildagliptin seems to be promoting lipolysis in the adipose tissue and, at the same 
time, increasing fatty acid oxidation in skeletal muscle [144]. 
However, in another study, C57BL/6 mice fed with a high fat diet became obese, but when 
treated with sitagliptin for 12 weeks it was observed a decrease in body weight which was originated 
by a decrease in the adipose tissue and a decrease in inflammation in the adipose tissue [159]. The 
decrease in the amount of adipose tissue was due to a decrease in the number of large adipocytes 
resulting in increased number of small adipocytes [159]. In addition, GcK+/- mice also fed with high fat 
diet, became obese with adipocytes hyperthrophy and, when des-fluo-sitagliptin was administred, the 
hyperthrophy was reduced [160]. Recently, another study was made where C57BL/6 mice were fed with 
high fat diet for 10 weeks to become obese and, after this period sitagliptin was given [161]. The results 
showed that this drug prevented the hyperinsulinemia, hyperglycaemia and dyslipidemia found in the 
non-treated obese animals [161]. Furthermore, WT mice showed accelerated weight gain and 
hyperinsulinemia, in contrast with DPPIV knockout mice that were resistant to the development of 
obesity and hyperinsulinemia [162]. This resistance was associated with reduced food intake and 
increased energy expenditure [162]. Moreover, Fischer 344 mutant (CD26 knockout mice) mice were 
also fed with high fat diet showing similar results: resistance to obesity and decreased food intake [163]. 
In addition, these animals also showed decreased blood glucose, increased insulin sensitivity and 
increased plasma levels of GLP-1 [163]. Other study with DPPIV deficient mice also showed similar 
results. These animals were fed with high fat diets, and showed reduced weight gain, when compared 
with wild type mice [164]. These differences were attributed to the reduction of intraabdominal fat 
depots. However, some contrasting results appeared in this study, since DPPIV knockout mice also 
showed increased NPY levels, which would lead to increased food intake [164]. Nevertheless, these 
animals still lost weight, suggesting that DPPIV action is directly on intraabdominal fat [164]. 
Finally, it was also necessary to understand if there was any difference in DPPIV expression 
and activity between lean and obese subjects. In obese people, DPPIV expression is 5-fold increased 
in visceral adipose tissue than in subcutaneous adipose tissue, contrasting with lean subjects where 
no difference was observed between fat depots [165]. DPPIV plasma concentration also appears to be 
positively correlated with adipocyte size, i.e., higher DPPIV concentrations correlate with bigger 
adipocytes [165]. Others showed that rats with a high fat diet, not only became obese, but also had 
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higher levels of plasma DPPIV, when compared with normal diet-fed rats [158]. These authors suggest 
that the post-prandial glucose elevation, which leads to visceral fat accumulation, may be responsible 
for the increase in plasma DPPIV [158]. The higher the levels of DPPIV, the lowest the levels of GLP-1 
and GIP, resulting in impaired glucose tolerance [158]. 
The alterations in DPPIV expression have been associated with changes in methylation in the 
promoter region of DPPIV gene. In human melanoma cell lines [166] and T-cell leukemia [167], where 
DPPIV expression is repressed, the promoter region appears to be hypermethylated. In addition, 
women with higher DPPIV gene methylation also showed lower DPPIV expression in their visceral 
adipose tissue, resulting in better plasma lipid profiles [168]. 
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1.9 Objectives of the present study: 
 
DPPIV is a peptidase released by the adipose tissue whose expression is increased in obese 
conditions [158, 165]. Previous studies demonstrated that this enzyme stimulates adipocyte differentiation 
and lipid accumulation (Ana P Marques; Joana Rosmaninho-Salgado, unpublished data). These 
evidences suggest that DPPIV is involved in the adipocyte metabolism and that this involvement might 
lead to an increase in the amount of adipose tissue as well as increased adipocyte diameter. A new 
class of DPPIV selective inhibitors is being commercialized for the treatment of T2DM [61]. These 
inhibitors are called gliptins and are associated with low risk of hypoglycaemia and weight loss or 
neutrality [144]. Three types of gliptins are already in the market: vildagliptin, sitagliptin and saxagliptin. 
The role played by these drugs in the adipose tissue is not yet well studied. NPY is one of DPPIV 
substrates and is also produced and secreted in the adipose tissue, among other tissues [94, 102, 103, 135]. 
Previous studies demonstrated that DPPIV stimulates lipid accumulation through cleavage of NPY1-36 
in NPY 3-36, which leads to activation of Y2 receptor (Ana P Marques; Joana Rosmaninho-Salgado, 
unpublished data). The mechanism by which NPY stimulates lipid accumulation is not yet known, nor 
the effects of gliptins on NPY-induced lipid accumulation. 
Therefore, to understand the role played by gliptins on the adipose tissue, the main goals of 
this study are: 
 
1) To evaluate the effect of gliptins on lipid accumulation, using a 3T3-L1 murine cell line 
2) To investigate whether gliptins can modulate lipolysis or adipogenesis 
3) To study the intracellular mechanism of action of gliptins 
4) To investigate the effect of gliptins on NPY-induced lipid accumulation and NPY’s 
mechanism of action 
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2.1 Material: 
 
3T3-L1 pre-adipocytes were obtained from the American type Culture Collection – LGC 
Promochem (Barcelona, Spain); Visceral and Epididymal Human pre-adipocytes cells and also the 
Lipolysis Assay Kit were obtained from Zenbio, Inc.; Dubeccos Modified Medium high glucose was 
obtained from Gibco (Barcelona, Spain); Cell plates were obtained from Orange Scientific (Geneva, 
Switzerland); Insulin, 3-isobutyl-1-methylxanthine (IBMX), dexamethasone, Oil red-O staining and 
isopropanol were obtained from Sigma (St Louis, MO, USA). NPY was obtained from Tocris 
Bioscience (Bristol, United Kingdom). BCA protein assay kit was obtained from Thermo Scientific 
Pierce. Antibody anti-PPARγ is from Santa Cruz Biotechnology (Heidelberg, Germany) and antibody 
anti-perilipin is from Cell Signaling, Inc. (Danvers, MA, USA). Hoechst 33342, antibody anti-rabbit IgG 
labelled with Alexa 488 were purchased from Molecular Probes (Invitrogen, Paisley, UK). rDPPIV and 
Vildagliptin (Galvus) were gently provided by Dr. Eric Grouzmann (Lausanne, Switzerlan). Sitagliptin 
(Januvia) was bought from Merck, and Saxagliptin (Onglyza) from Bristol-Myers Squib and Astra 
Zeneca. 
 
 
2.2 Methods: 
 
2.2.1 Cell culture 
 
The murine pre-adipocyte cell line (3T3-L1) was plated in 22.1 cm2 flasks and maintained in a 
humidified atmosphere of 5 % CO2-95 % air. Cells were grown in Dubeccos Modified Medium (DMEM-
F12) high glucose with phenol red and supplemented with 2.5 mM l-glutamine, 4.5 g/L glucose, 1.5 g/L 
NaHCO3, 10% heat-inactivated fetal bovine serum (FBS) (45ºC, 30min.), 100U/mL penicillin, 100U/mL 
streptomycin and 0.25 µg/mL amphotericin B. At 80 % confluence, cell culture was splited 1:10 by 
incubating cells with trypsin solution (37ºC, 3min.) and subcultured in 22.1 cm2 polystyrene culture 
plates. 
 
 
2.2.2 Cell differentiation conditions 
 
Pre-adipocytes were plated in 24-well plates (25 000 cells/well) and in 12-well plates (50 000 
cells/well), until they reach confluence (day 0). After 2 days, the medium was removed and replaced 
by DMEM supplemented with a differentiation cocktail: IBMX (0.5 mM) and dexamethasone (0.25 µM) 
(day 2). After 3 days (day 5), the differentiation cocktail was removed and the culture medium changed 
to DMEM-HG. Every 2 days the medium was renewed until day 9. Cell incubation with insulin (1 
µg/mL) was considered as the positive control. To test the effect of the different drugs in cell 
differentiation and lipid accumulation, these were incubated with insulin, together with selective 
inhibitors of rDPPIV (vildagliptin, sitagliptin and saxagliptin); with the selective inhibitors (without 
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insulin); and also with rDPPIV, in the presence and in the absence of the selective inhibitors. The 
negative control was cells that were not treated with insulin nor any other drug. 
 
 
2.2.3 Oil red-O staining 
 
Nine days after the induction of pre-adipocyte differentiation, cells were washed twice with 
Phosphate buffered saline (PBS) buffer and fixed with p-formaldehyde (4% in PBS) for 30 min at room 
temperature. Cells were then washed twice with PBS and once with distilled water. Cells were stained 
with Oil red-O dye (6:4, 0.6 % Oil red-O dye in water) for one hour and washed three times with water. 
Finally, Oil red-O dye was dissolved in 200µL of isopropanol. Absorbance was measured at 450 and 
570 nm. 
 
 
2.2.4 Immunocytochemistry 
 
Following fixation and permeabilization, nonspecific binding was blocked with 3% BSA. Cells 
were incubated with primary antibody, anti-PPARγ (1:500) or anti-Perilipin A (1:100), for 90 minutes, at 
room temperature. After washing with PBS, cells were incubated with secondary antibodies for 1hour 
(1:200, anti-rabbit conjugated with Alexa Fluor 488), at room temperature. All antibodies were 
prepared in blocking solution (3 % BSA). Nuclei were labelled with Hoechst 33342 (1 µg/mL) for 3 
minutes. Coverslips were mounted on glass slides and visualised on a fluorescence microscope 
(Axioskop 2 Plus, Zeiss, Jena, Germany), where images were acquired with the Axiovision software; 
or using a laser scanning microscope LSM 510 META (Zeiss, Jena, Germany). 
 
 
2.2.5 Total Protein extracts and Quantification 
 
Cells were placed on ice, rinsed twice with ice-cold PBS and then lysed with RIPA buffer (50 
mM Tris-HCl pH=8, 150nM NaCl, 1 % Triton, 0.5 % SDC, 0.1 % SDS) containing 100 µM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT), 1 µg/mL quimostatin, 1 µg/mL 
leupeptin, 1 µg/mL antiparin, 5 µg/mL pepstatin A (CLAP) and 1 mM ortovanadate, pH=7.4. Lysates 
were centrifuged at 3300 x g for 10 minutes at 4ºC, and the supernatants collected. 
Protein concentration was determined using the BCA protein assay, where bovine serum 
albumin (BSA) was used to generate the standard curve. 
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2.2.6 Western blotting 
 
Proteins were denatured by adding to each sample 1/5 of its volume in 6x concentrated 
denaturing solution, followed by heating to 95ºC, for 5 minutes.  
Proteins were loaded in a 4-10% discontinuous polyacrylamide gel, in the presence of SDS (SDS-
PAGE), and then separated by electrophoresis. Protein concentration was mainly between 40 and 60 
µg/µL, depending on the antibody being used. Following gel electrophoresis, proteins were 
electrophoretically transferred from the gel to a polyvinylidene fluoride membrane (90 minutes at 750 
mA). Prior to the transfer, membranes were activated with methanol. When the transfer was 
completed, membranes were blocked in 5 % non-fat milk in 0.1 % Tween 20 (TBS-T), for 60 minutes. 
Antibodies incubation was performed overnight (4ºC) with either rabbit polyclonal anti-PPARγ 
(1:500) or anti-Perilipin (1:500), in 1% (m/v) of non-fat milk in TBS-T. To normalize protein 
concentration, membranes were then incubated with anti-β-actin (1:20000). After incubation, 
membranes were firstly washed for 30 minutes in TBS-T, secondly incubated with an alkaline 
phosphatase-conjugated anti-rabbit (1:200) or anti-mouse (1:200), for 30 minutes at room 
temperature, and finally, after being washed for 30 minutes in TBS-T, immunorreactive detection was 
performed by chemifluorescence with ECF substrate. Fluorescence intensity was quantified by 
Quantity One (Biorad). 
 
 
2.2.7 Lipolysis Assay Kit (Glycerol Quantification)  
 
A standard curve was prepared one hour prior to the assay. Seven days after the initiation of 
the differentiation protocol, 25 µL of media was removed from each condition and added to a specific 
well in a 96 well plate. Glycerol Reagent A was then added to each well, containing either the media or 
the standards. Absorbance was measured at 570 nm, after 15 minutes incubation at room 
temperature. 
Simultaneously, total protein extracts were made and quantified, as described above. All 
absorbances were then normalized with the protein amount obtained in each sample. 
 
 
2.2.8 Statistical analysis 
 
Results were expressed as mean ± standard error of the mean (SEM). Data was analysed 
using one-way analysis of variance (ANOVA) followed by Dunnet’s test. A value of p<0.05 was 
considered significant. Prism 5 (GraphPad Software, San Diego, CA) was used for all statistical 
analysis. 
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3.1 The role of gliptins on lipid accumulation 
 
3.1.1 The role of gliptins on DPPIV-induced lipid accumulation 
 
Previous studies in our laboratory showed that DPPIV induces lipid accumulation (Ana P. 
Marques; Joana Rosmaninho-Salgado, unpublished data). To study the effect of gliptins on lipid 
accumulation induced by DPPIV, adipocytes were incubated with rDPPIV (50 µg/mL) in the presence 
or absence of vildagliptin (2 nM), sitagliptin (20 nM) or saxagliptin (1 nM) during 7 days. Lipid 
accumulation was analysed using the Oil red-O staining assay. All three gliptins reduced rDPPIV-
induced lipid accumulation: vildagliptin reduced 17.3 ± 3.1%, sitagliptin 29.9 ± 4.3% and saxagliptin 
25.5 ± 5.6%, respectively, compared to lipid accumulation induced by rDPPIV (figure 3.1). 
 
 
Figure 3.1. – Gliptins decrease rDPPIV-induced lipid accumulation. 
Adipocytes were incubated with rDPPIV (50 µg/mL) in the presence or absence of the DPPIV selective inhibitors 
vildagliptin (2 nM), sitagliptin (20 nM) and saxagliptin (1 nM) during 7 days. The Oilred O-staining assay was 
performed as described in Materials and Methods (see section 2). Results are expressed as the percentage of 
lipid accumulation compared to rDPPIV. Mean ± SEM, 3 to 7 different independent experiments, each condition 
performed in triplicate.	  *p<0.05 , ** p < 0.01 and ***p<0.001, compared to rDPPIV (50 µg/mL). One-way ANOVA 
was used as statistical test. 
 
 
3.1.2 The role of gliptins on basal lipid accumulation 
 
Differentiated adipocytes also express and release DPPIV [158]. To study the effect of gliptins 
have on basal lipid accumulation, adipocytes were incubated with vildagliptin (2 nM), sitagliptin (20 
nM) and saxagliptin (1 nM) during 7 days. Basal lipid accumulation was inhibited in the presence of 
gliptins: vildagliptin, sitagliptin, saxagliptin inhibited 29.4 ± 8.3%, 27.9 ± 8.4% and 21.5 ± 3.6%, 
respectively, compared to control (figure 3.2). 
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Figure 3.2. - The role of gliptins on basal lipid accumulation. 
Adipocytes were incubated with the DPPIV inhibitors: vildagliptin (2 nM), sitagliptin (20 nM) and saxagliptin (1 
nM), for 7 days. The Oilred O-staining assay was performed as described in Materials and Methods (see section 
2). Results are expressed as the percentage of lipid accumulation compared to control. Mean ± SEM, 6 to 7 
different independent experiments, each condition performed in triplicate.	  *p<0.05 and ** p < 0.01, compared to 
control. One-way ANOVA was used as statistical test. 
 
 
3.1.3 The role of gliptins on lipid accumulation induced by insulin 
 
Insulin stimulates lipid accumulation, by preventing lipolysis [34] and by inducing lipogenesis [1]. 
To study the effect of gliptins on lipid accumulation induced by insulin, adipocytes were incubated with 
insulin (1 µg/mL) in the presence or absence of vildagliptin (2 nM), sitagliptin (20 nM), or saxagliptin (1 
nM). All three gliptins decreased insulin-induced lipid accumulation: vildagliptin, sitagliptin and 
saxaglitin inhibited 22.4 ± 7.1%, 16.3 ± 3.5% and 23.8 ± 4.1%, respectively, compared to insulin 
(figure 3.3). 
 
 
Figure 3.3. – Gliptins reduce insulin-stimulated lipid accumulation. 
Adipocytes were incubated with insulin (1 µg/mL) in the presence or absence of the DPPIV selective inhibitors 
vildagliptin (2 nM), sitagliptin (20 nM) and saxagliptin (1 nM) during 7 days. The Oilred O-staining assay was 
performed as described in Materials and Methods (see section 2). Results are expressed as the percentage of 
lipid accumulation compared to insulin. Mean ± SEM, 6 to 5 different independent experiments, each condition 
performed in triplicate. All values were normalized to 100% of insulin *p<0.05 and ** p < 0.01, compared to insulin 
(1 µg/mL). One-way ANOVA was used as statistical test. 
 
  
Results 
	  
	  
	  
35	  
3.2 Effect of gliptins on lipolysis 
 
 The effect of gliptins on lipid accumulation was also studied by analysing the effect of gliptins 
on glycerol release, which is a measure of lipolysis. We observed that vildagliptin, sitagliptin and 
saxagliptin did not affect basal glycerol release, when compared to control (figure 3.4). 
 
 
Figure 3.4. – Gliptins do not affect basal glycerol release. 
Adipocytes were incubated with isoproterenol (1 µM), considered as a positive control, insulin (1 µg/mL) as the 
negative control and vildagliptin (2 nM), sitagliptin (20 nM) or with saxagliptin (1 nM), during 7 days The Lipolysis 
Assay kit was performed as described in Materials and Methods (see section 2). Results are expressed as the 
percentage of glycerol release compared to basal control. Mean ± SEM, 3 to 4 different independent experiments, 
each condition performed in triplicate. One-way ANOVA was used as statistical test. 
 
 
Perilipin is a protein only expressed in differentiated adipocytes [36] and is present at the 
surface of lipid droplets and protects them against several lipases [35]. When lipolysis occurs perilipin 
levels decrease [38]. 
 Adipocytes were incubated with vildagliptin (2 nM), sitagliptin (20 nM) and saxagliptin (1 nM) 
during 7 days, and the perilipin levels were evaluated by Western Blotting assay. It was observed that 
gliptins do not affect perilipin levels (figure 3.5). 
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Figure 3.5. – Gliptins do not affect perilipin levels 
Adipocytes were incubated with vildagliptin (2 nM), sitagliptin (20 nM) and saxagliptin (1 nM) during 7 days. Whole 
cell extracts were performed and Western Blotting assay against perilipin (62 KDa) was performed as described 
in Materials and Methods (see section 2). Results are expressed as the percentage of perilipin levels, compared 
to control. Mean ± SEM, 8 different independent experiments, each condition performed in triplicate. One-way 
ANOVA was used as statistical test. 
 
 
Before being degraded in lysosomes, perilipin leaves the surface of lipid droplets [38]. We 
evaluated the effect of gliptins on perilipin location on the surface of the lipid droplets of adipocyte by 
immunocytochemistry assay. Both in the presence or absence of gliptins, adipocytes showed perilipin 
(green) surrounding the surface of the lipid droplets (figure 3.6), suggesting that gliptins do not affect 
perilipin cell location. 
 
 
Figure 3.6. – Gliptins do not change perilipin location 
Representative images of differentiated adipocytes, showing perilipin staining (green) on the surface of lipid 
droplets and in the cytoplasm. These cells were treated with vildagliptin (2 nM), sitagliptin (20 nM) and saxagliptin 
(1 nM), during 7 days. Nuclei were labelled with Hoescht 33342 (blue). Immunocytochemistry was performed as 
described in Materials and Methods (see section 2). Representative images are shown. 
 
 
 The effect of DPPIV on lipolysis was also investigated by measuring glycerol release. 
Adipocytes were incubated with isoproterenol (1 µM, positive control) [33], insulin (1 µg/mL, negative 
control) [34] and recombinant DPPIV (rDPPIV, 50 µg/mL), during 7 days. Isoproterenol induced an 
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increase of 28.0 ± 3.0 % on glycerol release, and insulin decreased 45.3 ± 8.7%. rDPPIV did not 
change glycerol release (figure 3.7). 
 
 
Figure 3.7. – DPPIV does not affect glycerol release. 
Adipocytes were incubated with isoproterenol (1 µM, positive control), insulin (1 µg/mL, negative control) or with 
rDPPIV for 7 days. Glycerol release into the medium was quantified using a Lipolysis Assay Kit. The 
Lipolysis Assay kit was performed as described in Materials and Methods (see section 2). Results are expressed 
as the percentage of glycerol release compared to basal control. Mean ± SEM, 2 to 4 different independent 
experiments, each condition performed in triplicate. ***p<0.001, compared to control. One-way ANOVA was used 
as statistical test. 
 
 
To evaluate the effect of DPPIV on perilipin levels, adipocytes were incubated with rDPPIV (50 
µg/mL) and Western blotting assay was performed. We observed that rDPPIV does not affect perilipin 
levels, when compared to control (figure 3.8). 
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Figure 3.8. – DPPIV does not change perilipin levels. 
Adipocytes were incubated with rDPPIV (50 µg/mL) during 7 days and whole cell extracts were performed. 
Western blotting assay was performed against the perilipin (62 KDa) immunoreactivity by Western Blotting, as 
described in Materials and Methods (see section 2). Results are expressed as the percentage of perilipin levels, 
compared to control. Mean ± SEM, 3 different independent experiments, each condition performed in triplicate. T-
test was used as statistical test. 
 
 
3.3 The role of gliptins on adipogenesis 
 
In figures 3.4, 3.5 and 3.6 we showed that gliptins do not reduce lipid accumulation by 
inducing lipolysis. Since PPARγ is a transcription factor crucial for pre-adipocyte differentiation into 
adipocytes [18] we investigated the role gliptins on PPARγ levels. Adipocytes were incubated with 
vildagliptin (2 nM), sitagliptin (20 nM) or saxagliptin (1 nM) and PPARγ levels were determined by 
Western-bloting The three gliptins reduce PPARγ levels in 19.9 ± 5.9%, 15.0 ± 3.5% and 14.7 ± 6.5%, 
respectively (figure 3.9). 
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Figure 3.9 – Gliptins decrease PPARγ levels. 
Adipocytes were incubated with vildagliptin (2 nM), sitagliptin (20 nM) and saxagliptin (1 nM), for 7 days. Whole 
cell extracts were assayed for PPARγ immunoreactivity by Western Blotting, as described in Materials and 
Methods (see section 2). Results are expressed as the percentage of PPARγ levels, compared to control. Mean ± 
SEM, 7 to 14 different independent experiments, each condition performed in triplicate. *p<0.05 and ** p < 0.01 
compared to control. One-way ANOVA was used as statistical test. 
 
 
Differentiated adipocytes maintain PPARγ levels in order to keep the differentiated state [1]. To 
evaluate if gliptins could revert the differentiated state of adipocytes, by decreasing PPARγ levels [1], 
we determined PPARγ levels in cells previously treated with insulin (1 µg/mL) in the presence or 
absence of gliptins. The results show that PPARγ levels decrease 13.0 ± 3.3 %, 16.1 ± 2.6 % and 16.7 
± 6.5 % in the presence of vildagliptin (2 nM), sitagliptin (20 nM) or saxagliptin (1 nM), respectively 
(figure 3.10). 
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Figure 3.10. – Gliptins are reducing insulin induced PPARγ levels. 
Adipocytes were incubated with insulin (1 µg/mL) in the presence or absence of vildagliptin (2 nM), sitagliptin (20 
nM) and saxagliptin (1 nM), for 7 days. Whole cell extracts were assayed for PPARγ immunoreactivity by Western 
Blotting, as described in Materials and Methods (see section 2). Results are expressed as the percentage of 
PPARγ levels, compared to insulin. Mean ± SEM, 5 to 9 different independent experiments, each condition 
performed in triplicate. *p<0.05 and ** p < 0.01, compared to insulin. One-way ANOVA was used as statistical 
test. 
 
To further understand the mechanism of gliptins on inhibiting lipid accumulation, we 
investigated the involvement of PKA pathway on this effect. We incubated adipocytes with vildagliptin 
(2 nM), in the presence or absence of the PKA inhibitor (H89, 1 µM) during 7 days. Using Oil red-O 
staining assay, we quantified lipid accumulation and the results showed that in the presence of H89, 
lipid accumulation increased to values close to control (figure 3.11). We also incubated adipocytes 
alone with H89 and no basal effect was observed. 
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Figure 3.11 – Gliptins inhibit lipid accumulation through PKA. 
Adipocytes were incubated with the vildagliptin (2 nM), in the presence or absence of the PKA inhibitor (H-89, 1 
µM), during 7 days. The Oilred O-staining assay was used as described in Materials and Methods (see section 2). 
Results are expressed as the percentage of lipid accumulation compared to control. Mean ± SEM, 8 different 
independent experiments, each condition performed in triplicate. ** p < 0.01, compared to control. One-way 
ANOVA was used as statistical test. 
 
 
 Since gliptins also decrease lipid accumulation induced by insulin, we also tested PKA 
pathway in the presence of insulin (1 µg/mL) and vildagliptin (2 nM). The results show that when PKA 
inhibitor is present lipid accumulation increased to amounts near those induced by insulin (figure 
3.12). 
 
 
 
Figure 3.12. – Vildagliptin inhibits insulin-stimulated lipid accumulation through PKA. 
Adipocytes were treated with insulin (1 µg/mL) and vildagliptin (2 nM), in the presence or absence of the PKA 
inhibitor (H-89,1 µM) during 7 days. The Oilred O-staining test was used as described in Materials and Methods 
(see section 2). Results are expressed as the percentage of lipid accumulation compared to insulin. Mean ± SEM, 
5 different independent experiments, each condition performed in triplicate. *p<0.05, compared to insulin. One-
way ANOVA was used as statistical test. 
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3.4 The role of gliptins on NPY-induced lipid accumulation 
 
Previous work showed that DPPIV stimulates lipid accumulation by cleaving NPY in a NPY Y2 
receptor agonist, the NPY3-36 fragment (Ana P Marques; Joana Rosmaninho-Salgado, unpublished 
data). We further investigated the role of NPY on lipid accumulation induced by DPPIV by studying the 
effect of gliptins on lipid accumulation induced by NPY. The results show that, all three gliptins reduce 
NPY-induced lipid accumulation (fig 3.13). Vildagliptin, sitagliptin and saxagliptin decreased 12.8 ± 
2.82 %, 32.9 ± 5.9 % and 24.9 ± 11.0 %, respectively, compared to NPY (figure 3.13). 
 
 
 
Figure 3.13. – Gliptins decrease NPY-induced lipid accumulation 
Adipocytes were incubated with NPY (100 nM) in the presence or absence of vildagliptin (2 nM), sitagliptin (20 
nM) and saxagliptin (1 nM) during 7 days. The Oil-red O-staining test was used, as described in Materials and 
Methods (see section 2). Results are expressed as the percentage of lipid accumulation compared to NPY. Mean 
± SEM, 5 different independent experiments, each condition performed in triplicate. *p<0.05 and ** p < 0.01, 
compared to NPY. One-way ANOVA was used as statistical test. 
 
 
We investigated the role of the PKA pathway on lipid accumulation induced by NPY. The 
results show that when NPY was incubated together with the PKA inhibitor H-89 (1 µM), the 
stimulatory effect of NPY on lipid accumulation was inhibited (figure 3.14). 
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Figure 3.14. – NPY stimulates lipid accumulation through PKA. 
Adipocytes were incubated with NPY (100 nM), in the presence or absence of H-89 (1 µM), for 7 days. The Oilred 
O-staining test was used as described in Materials and Methods (see section 2). Results are expressed as the 
percentage of lipid accumulation compared to control. Mean ± SEM, 7 different independent experiments, each 
condition performed in triplicate. *p<0.05, compared to control; +p<0.05 compared to NPY. One-way ANOVA was 
used as statistical test. 
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DPPIV selective inhibitors are the new class of drugs for the treatment of T2DM [61]. Until 
2010, vildagliptin, sitagliptin, saxagliptin, were the only three gliptins commercialized in Europe and, 
except from vildagliptin, accepted by FDA. The present work is the first to suggest that these gliptins 
reduce lipid accumulation by inhibiting adipogenesis via PKA. 
Using a 3T3-L1 cell line, we showed that gliptins reduce both basal and stimulated lipid 
accumulation in adipocytes. Moreover, unpublished data from our group demonstrated that DPPIV 
stimulates lipid accumulation and, with the present study it is also suggested that gliptins inhibit the 
stimulatory effect induced by DPPIV. In fact, our results are consistent with previous studies where 
type 2 diabetic (T2DM) mice treated with sitagliptin had lower fat depots and a decrease in adipocytes 
size [151]. It was also observed that C57BL/6 obese mice treated with sitagliptin for 12 weeks lost 
weight due to a decrease in adipose tissue [159]. Also, β-cell-specific glucokinase haploinsufficient (Gck 
+/-)) diabetic mice, under a high fat diet, became obese and with adipocyte hypertrophy. When des-
fluo-sitagliptin was administered the hypertrophy was reduced [160], demonstrating the importance of 
DPPIV selective inhibitors on the adipose tissue.  
Taking into account that gliptins have an important role on lipid accumulation, we studied the 
role of gliptins on lipolysis and adipogenesis. Our studies show that gliptins do not induce lipolysis 
(figures 4.1, 4.2 and 4.3). Vildagliptin, sitagliptin and saxagliptin, did not induce glycerol release to the 
medium, when compared to a basal situation. It is also described that when occurs a mobilization of 
perilipin from the surface of lipid droplets it indicates that lipolysis is occurring [38]. In our work we 
demonstrated that perilipin levels and its physical position around lipid droplets were similar in all 
conditions, indicating that gliptins are not involved in lipolysis. There is a study performed by others 
using different experimental approaches suggesting opposite results: vildagliptin given to T2DM 
patients increased post-prandial glycerol release in the adipose tissue [146].  
 We further investigated the role of gliptins on the inhibition of lipid accumulation. Several 
studies state that DPPIV plasma activity is increased in obese states [158, 165], and perilipin levels are 
decreased when compared to lean individuals and, consequently, lipolysis is increased [169-171]. So it 
would be expected that DPPIV induced lipolysis. However, our results show that DPPIV has no effect 
on perilipin levels or glycerol release and, consequently, no effect on lipolysis, (see figures 4.4 and 
4.5.). On the other hand, the absence of effect of DPPIV on lipolysis is in agreement with previous 
results of our group which demonstrated that DPPIV induced not only lipid accumulation but also 
PPARγ expression (Ana P Marques; Joana Rosmaninho-Salgado, unpublished data). Other groups 
also observed the importance of DPPIV on adipose tissue formation. DPPIV knock-out mice and 
DPPIV deficient rats were resistant to obesity under high fat diets [162-164] and several studies state that 
DPPIV plasma activity is increased in obesity [158, 165]. In our work we also show that all the three 
gliptins were able to inhibit PPARγ expression induced by DPPIV (see figures 3.9 and 3.10). However, 
this role that gliptins have on PPARγ expression is contrary to the effect that other anti-diabetics have 
[172]. Thiazolidinediones (TZDs), for example, decrease insulin resistance by enhancing PPARγ 
expression, resulting in increased body weight [172]. On the contrary, gliptins act to increase the half-life 
of incretins and not to increase PPARγ expression [61, 155]. Several studies state that pre-adipocytes 
lacking the PPARγ gene are unable to differentiate into mature adipocytes and consequently, unable 
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to accumulate triglycerides [18]. In addition, when in differentiated adipocytes PPARγ expression is 
blocked, adipocytes dedifferentiate and lose the ability to accumulate lipid droplets [1]. Accordingly, it 
makes sense that gliptins reduce lipid accumulation by blocking the adipogenic process through 
inhibition of PPARγ expression. Therefore, we suggest that gliptins have an anti-adipogenic action on 
adipocytes leading to a decrease on lipid accumulation. This action may result in a decrease in total 
body weight as it was observed in mice that were under high fat diets and, with the administration of 
sitagliptin, lost weight [159, 160]. 
We further investigated the intracellular pathways involved on lipid accumulation modulated by 
gliptins. Our results show that gliptins action is through protein kinase A (PKA). Others have already 
showed that the protective action of sitagliptin against myocardial ischemia is via cAMP-dependent 
PKA activation [173]. Several studies demonstrated that PKA activation is necessary during the early 
stages of differentiation [24] but leads to inhibition of late stage of adipogenesis [25, 28, 29]. Furthermore, it 
was reported that mice continually expressing PKA had a reduction on the amount of adipose tissue 
and that these mice were resistant to diet-induced obesity [174]. The inhibitory role of PKA on 
adipogenesis was also demonstrated by using a PKA inhibitor in 3T3-L1 cells leading to a reduction 
on the time span needed for full adipogenesis [29]. All these results corroborate our hypothesis that 
gliptins lead to inhibition of adipogenesis by activating PKA.  
NPY is a well-known substrate of DPPIV and it is also described that it increases lipid 
accumulation through stimulation of adipogenesis [94, 102, 103, 137] and inhibition of lipolysis [53, 94, 107]. In 
this study, we showed that gliptins decrease NPY-induced lipid accumulation. It is also described that 
in adipocytes, NPY decreases cAMP levels [30, 108] promoting adipogenesis [108]. In fact, in our study we 
showed that the stimulatory effect of NPY occurs through PKA pathway (figure 7.1.2). In addition, 
several studies demonstrated that NPY anti-lipolytic action is also mediated by PKA [37, 106, 108, 138]. 
Moreover, it was also demonstrated that NPY, in mouse chromaffin cells, modulates catecholamine 
release via PKA [175]. Also in a human neuroblastoma cell line SK-N-MC, NPY upregulates gene 
expression through modulation of cAMP levels and, consequently PKA activity [176, 177]. Other groups 
also studied the role of NPY on lipid accumulation. Some have suggested that NPY stimulates 
adipogenesis through NPY Y1 receptor activation, both in primary rat adipocytes and in 3T3-L1 pre-
adipocytes [103]. Others have showed that this effect is through NPY Y2 receptor activation, in 3T3-L1 
pre-adipocytes [178]. In addition, some of the unpublished data of our group showed that DPPIV 
stimulates adipocyte proliferation and lipid accumulation through activation of the Y2 receptor. Here, 
we purpose that NPY stimulates lipid accumulation through Y2 receptor in a PKA dependent manner.  
 
In conclusion, in this study we demonstrate that vildagliptin, sitagliptin and saxagliptin have an 
anti-adipogenic effect via PKA, resulting in a decrease on lipid accumulation without lipolysis increase. 
In addition, NPY-stimulated lipid accumulation through Y2 is dependent on PKA and this NPY effect is 
blocked by these three gliptins. These results suggest that gliptins can be used as new putative 
pharmacological strategies to prevent adipose tissue increase without the risk of dyslipidemia. 
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Figure 4.1 – Gliptins inhibition mechanism of DPPIV-induced lipid accumulation 
A) DPPIV stimulates adipogenesis and, consequently lipid accumulation. To increase adipogenesis DPPIV 
increases PPARγ levels and, simultaneously cleaves NPY1-36 into NPY3-36. The cleaved form of NPY activates the 
NPY Y2 receptor that, by modulation of PKA, increases lipid accumulation. B) Gliptins reduce DPPIV-induced lipid 
accumulation is due to increased PKA activation that, consequently, leads to a decrease of PPARγ levels. This 
reduction blocks adipogenesis and decreases lipid accumulation. On the same time, DPPIV is no longer able to 
cleave NPY1-36 into NPY3-36. The not cleaved form of NPY is not a NPY Y2 agonist and, as a result, this receptor is 
not activated and lipid accumulation is not stimulated. Dipeptidyl-peptidase IV, DPPIV; peroxisome proliferator-
activated receptor γ: PPAR γ; Neuropeptide Y: NPY; Protein kinase A: PKA; Neuropeptide Y Y2 receptor: NPY Y2. 
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The results presented in this thesis suggest the following main conclusions: 
 
1. Vildagliptin, sitagliptin and saxagliptin inhibit DPPIV-induced lipid accumulation; 
2. Vildagliptin, sitagliptin and saxagliptin inhibit adipogenesis by decreasing PPARγ levels 
through activation of PKA pathway; 
3. Vildagliptin, sitagliptin and saxagliptin do not induce lipolysis; 
4. NPY-stimulated lipid accumulation occurs through PKA; 
5. Vildagliptin, sitagliptin and saxagliptin inhibit NPY-stimulated lipid accumulation; 
 
In summary, in this work we show that gliptins are able to inhibit adipogenesis, through 
activation of PKA pathway and that this inhibition leads to a decrease on lipid accumulation and has 
no effect on lipolysis. It was also observed that NPY-stimulated lipid accumulation is also through 
modulation of PKA and that this stimulus can be inhibit by gliptins. We suggest that DPPIV inhibitors 
may prevent the increase of adipose tissue without the risk of dyslipidemia.  
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